Data Shows Potential for Change in Standard of Care for Transplant-Ineligible Myeloma

Andrew L. Pecora, MD, FACP, CPE, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results from the phase III MAIA trial in which the triplet regimen of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) was compared to lenalidomide plus dexamethasone alone as a treatment for patients with newly diagnosed multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant (ASCT). The addition of daratumumab to lenalidomide plus dexamethasone demonstrated a significant advantage over the current standard of care (SOC), which currently includes ASCT. Pecora believes the data from this trial will be practice changing for these patients. Though there is only a relatively small percentage of patients that are not eligible to receive ASCT, outcomes have been limited for these patients. However, the MAIA trial led to significant improvements in outcomes. Progression-free survival, in particular, was improved with the triplet regimen. Pecora says DRd will likely become the new SOC for patients with newly diagnosed multiple myeloma who are ineligible to receive ASCT. For more resources and information regarding anticancer targeted therapies in multiple myeloma: http://targetedonc.com/resource-cente...